Evidence map›Paper›PMID 33608690›Full record

ReviewNature reviews. Clinical oncology2021

Diagnosis, grading and management of toxicities from immunotherapies in children, adolescents and young adults with cancer.

Dristhi Ragoonanan, Sajad J Khazal, Hisham Abdel-Azim, David McCall, Branko Cuglievan, Francesco Paolo Tambaro, Ali Haider Ahmad, Courtney M Rowan, Cristina Gutierrez, Keri Schadler and 32 more

Erratum issuedOpen access · hybridAbstract readReviewConsensus Statement
PubMed Full text at PMC Publisher
In one paragraph

Review in Nature reviews. Clinical oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 31 papers.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed
14.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 55 citations in OpenAlex.

  1. Article
  2. A pharmacovigilance data-driven approach to reveal high fatal adverse events following checkpoint immunotherapy.Proceedings of the National Academy of Sciences of the United States of America · 2026
    Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Review
  12. Article
  13. Article
  14. Review
  15. Review
  16. Review
  17. Article
  18. Review
  19. The broad spectrum of cardiotoxicities from immunotherapies.Frontiers in cardiovascular medicine · 2023
    Article
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

42 authors at 15 institutions in 3 countries.

Dristhi RagoonananDepartment of Pediatrics, CARTOX Program, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. DRagoonanan@mdanderson.org.ORCID http://orcid.org/0000-0002-8199-9404
Sajad J KhazalDepartment of Pediatrics, CARTOX Program, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0002-3731-608X
Hisham Abdel-AzimDepartment of Pediatrics, Blood and Marrow Transplantation Program, Keck School of Medicine, University of Southern California, Children's Hospital Los Angeles, Los Angeles, CA, USA.
David McCallDepartment of Pediatrics, CARTOX Program, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0003-2297-9670
Branko CuglievanDepartment of Pediatrics, CARTOX Program, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Francesco Paolo TambaroUOC SIT-TMO AORN Santobono-Pausilipon, Napoli, Italy.
Ali Haider AhmadDepartment of Pediatrics, CARTOX Program, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Courtney M RowanDepartment of Pediatrics, Division of Critical Care, Indiana University School of Medicine, Riley Hospital for Children, Indianapolis, IN, USA.
Cristina GutierrezDepartment of Critical Care, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Keri SchadlerDepartment of Pediatrics Research, Center for Energy Balance in Cancer Prevention and Survivorship, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Shulin LiDepartment of Pediatrics Research, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Matteo Di NardoPediatric Intensive Care Unit, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.
Linda ChiDivision of Diagnostic Imaging, Neuroradiology Department, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Alison M GulbisDivision of Pharmacy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Basirat ShoberuDepartment of Pediatrics, CARTOX Program, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Maria E MirelesDivision of Pharmacy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Jennifer McArthurDepartment of Pediatrics, Division of Critical Care, St Jude Children's Research Hospital, Memphis, TN, USA.
Neena KapoorDepartment of Pediatrics, Blood and Marrow Transplantation Program, Keck School of Medicine, University of Southern California, Children's Hospital Los Angeles, Los Angeles, CA, USA.
Jeffrey MillerDepartment of Pediatrics, CARTOX Program, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Julie C FitzgeraldDepartment of Anesthesia and Critical Care, University of Pennsylvania Perelman School of Medicine, The Children's Hospital of Philadelphia, Philadelphia, PA, USA.ORCID http://orcid.org/0000-0001-9936-9569
Priti TewariDepartment of Pediatrics, CARTOX Program, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Demetrios PetropoulosDepartment of Pediatrics, CARTOX Program, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Jonathan B GillDepartment of Pediatrics, CARTOX Program, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Christine N DuncanPediatric Hematology-Oncology, Dana-Farber Cancer Institute, Harvard University, Boston, MA, USA.
Leslie E LehmannPediatric Hematology-Oncology, Dana-Farber Cancer Institute, Harvard University, Boston, MA, USA.
Sangeeta HingoraniDepartment of Pediatrics, University of Washington School of Medicine, Division of Nephrology, Seattle Childrens and the Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Joseph R AngeloRenal Section, Baylor College of Medicine, Texas Children's Hospital, Houston, TX, USA.
Rita D SwinfordDepartment of Pediatrics, Division of Pediatric Nephrology, McGovern Medical School, The University of Texas Health Science Center, Houston, TX, USA.
Marie E SteinerDepartment of Pediatrics, University of Minnesota, Minneapolis, MN, USA.
Fiorela N Hernandez TejadaDepartment of Pediatrics, CARTOX Program, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Paul L MartinDepartment of Pediatrics, Division of Transplant and Cellular Therapy, Duke Children's Hospital, Duke University, Durham, NC, USA.
Jeffery AulettaDivision of Hematology, Oncology, Bone Marrow Transplant and Infectious Diseases, Nationwide Children's Hospital, Ohio State University, Columbus, OH, USA.
Sung Won ChoiDepartment of Pediatrics, University of Michigan, Ann Arbor, MI, USA.ORCID http://orcid.org/0000-0002-6321-3834
Rajinder BajwaDivision of Pediatric Hematology/Oncology/Blood and Marrow Transplantation, Nationwide Children's Hospital, The Ohio State University, Columbus, OH, USA.ORCID http://orcid.org/0000-0003-4498-0322
Natalie Dailey GarnesDepartment of Infectious Disease, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0002-4016-4929
Partow KebriaeiDepartment of Stem Cell Transplantation and Cellular Therapy, CARTOX Program, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Katayoun RezvaniDepartment of Stem Cell Transplantation and Cellular Therapy, CARTOX Program, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
William G WierdaDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Sattva S NeelapuDepartment of Lymphoma and Myeloma, CARTOX Program, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0003-1045-4914
Elizabeth J ShpallDepartment of Stem Cell Transplantation and Cellular Therapy, CARTOX Program, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Selim CorbaciogluDepartment of Pediatric Hematology, Oncology and Stem Cell Transplantation, University of Regensburg, Regensburg, Germany.
Kris M MahadeoDepartment of Pediatrics, CARTOX Program, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0003-2649-9674
The University of Texas MD Anderson Cancer Center · USHarvard University · USNationwide Children's Hospital · USUniversity of Southern California · USBambino Gesù Children's Hospital · ITBaylor College of Medicine · USChildren's Hospital of Philadelphia · USDuke University · USRiley Hospital for Children · USSt. Jude Children's Research Hospital · USThe University of Texas Health Science Center at Houston · USUniversity of Michigan · USUniversity of Minnesota · USUniversity of Regensburg · DEUniversity of Washington · US

Funding

Develop CTC capture technology for both mesenchymal and non-mesenchymal tumorsR01EB026291 · NIBIB · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI LI, SHULIN · 2018 to 2021
$1.4M
Prognostic biomarkers for respiratory failure post hematopoietic cell transplantationK23HL150244 · NHLBI · INDIANA UNIVERSITY INDIANAPOLIS · PI ROWAN, COURTNEY · 2020 to 2024
$899k
NHLBI NIH HHS K23 HL150244NIBIB NIH HHS R01 EB026291
6 · The paper itself

Abstract

Cancer immunotherapies are associated with remarkable therapeutic response rates but also with unique and severe toxicities, which potentially result in rapid deterioration in health. The number of clinical applications for novel immune effector-cell therapies, including chimeric antigen receptor (CAR)-expressing cells, and other immunotherapies, such as immune-checkpoint inhibitors, is increasing. In this Consensus Statement, members of the Pediatric Acute Lung Injury and Sepsis Investigators (PALISI) Network Hematopoietic Cell Transplantation-Cancer Immunotherapy (HCT-CI) Subgroup, Paediatric Diseases Working Party (PDWP) of the European Society of Blood and Marrow Transplantation (EBMT), Supportive Care Committee of the Pediatric Transplantation and Cellular Therapy Consortium (PTCTC) and MD Anderson Cancer Center CAR T Cell Therapy-Associated Toxicity (CARTOX) Program collaborated to provide updated comprehensive recommendations for the care of children, adolescents and young adults receiving cancer immunotherapies. With these recommendations, we address emerging toxicity mitigation strategies, we advocate for the characterization of baseline organ function according to age and discipline-specific criteria, we recommend early critical care assessment when indicated, with consideration of reversibility of underlying pathology (instead of organ failure scores) to guide critical care interventions, and we call for researchers, regulatory agencies and sponsors to support and facilitate early inclusion of young patients with cancer in well-designed clinical trials.

Indexed as

Drug-Related Side Effects and Adverse ReactionsTransfusion ReactionAdolescentAdultAge FactorsAge of OnsetAntineoplastic Agents, ImmunologicalChildHematopoietic Stem Cell TransplantationHumansImmunologic FactorsImmunotherapyNeoplasmsReceptors, Chimeric AntigenSeverity of Illness IndexTransfusion-Related Acute Lung InjuryAntineoplastic Agents, ImmunologicalImmunologic FactorsReceptors, Chimeric Antigen

Identifiers

PMID33608690
PMCPMC9393856
OpenAlexW3131565677

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.